These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 37149726)

  • 1. Real-World Effectiveness of Nirmatrelvir/Ritonavir on Coronavirus Disease 2019-Associated Hospitalization Prevention: A Population-based Cohort Study in the Province of Quebec, Canada.
    Kaboré JL; Laffont B; Diop M; Tardif MR; Turgeon AF; Dumaresq J; Luong ML; Cauchon M; Chapdelaine H; Claveau D; Brosseau M; Haddad E; Benigeri M
    Clin Infect Dis; 2023 Sep; 77(6):805-815. PubMed ID: 37149726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
    Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA
    Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina.
    Henderson HI; Wohl DA; Fischer WA; Bartelt LA; van Duin D; Agil DM; Browne LE; Li KP; Moy A; Eron JJ; Napravnik S
    J Antimicrob Chemother; 2024 Apr; 79(4):859-867. PubMed ID: 38380946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study.
    Rajme-López S; Martinez-Guerra BA; Román-Montes CM; Tamez-Torres KM; Tello-Mercado AC; Tepo-Ponce KM; Segura-Ortíz Z; López-Aguirre A; Gutiérrez-Mazariegos ODR; Lazcano-Delgadillo O; Nares-López R; González-Lara MF; Kershenobich-Stalnikowitz D; Sifuentes-Osornio J; Ponce-de-León A; Ruíz-Palacios GM
    Ther Adv Infect Dis; 2024; 11():20499361241236582. PubMed ID: 38545451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission.
    Wee LE; Tay AT; Chiew C; Young BE; Wong B; Lim R; Lee CL; Tan J; Vasoo S; Lye DC; Tan KB
    Clin Microbiol Infect; 2023 Oct; 29(10):1328-1333. PubMed ID: 37331509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies.
    Mesfin YM; Blais JE; Kibret KT; Tegegne TK; Cowling BJ; Wu P
    J Antimicrob Chemother; 2024 Sep; 79(9):2119-2131. PubMed ID: 38817046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19 in the era of vaccination and Omicron: An updated meta-analysis.
    Ombelet S; Castanares-Zapatero D; Desimpel F; Hulstaert F; Stordeur S; Roberfroid D
    J Med Virol; 2024 Feb; 96(2):e29434. PubMed ID: 38376947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study.
    Dryden-Peterson S; Kim A; Kim AY; Caniglia EC; Lennes IT; Patel R; Gainer L; Dutton L; Donahue E; Gandhi RT; Baden LR; Woolley AE
    Ann Intern Med; 2023 Jan; 176(1):77-84. PubMed ID: 36508742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
    Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
    J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data.
    Petrakis V; Rafailidis P; Trypsianis G; Papazoglou D; Panagopoulos P
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nirmatrelvir/Ritonavir Regimen for Mild/Moderately Severe COVID-19: A Rapid Review With Meta-Analysis and Trial Sequential Analysis.
    Okoli GN; Askin N; Rabbani R
    Ann Fam Med; 2024; 22(4):336-346. PubMed ID: 39038972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
    Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
    Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
    Bajema KL; Berry K; Streja E; Rajeevan N; Li Y; Mutalik P; Yan L; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Ioannou GN
    Ann Intern Med; 2023 Jun; 176(6):807-816. PubMed ID: 37276589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective cohort study of prescribing outcomes in outpatients treated with nirmatrelvir-Ritonavir for COVID-19 in an interdisciplinary community clinic.
    Leung V; Gill S; Llanes A; Khawaja A; Stagg A; McCready J; Jacubovich M; Ho G; Powis J; Kandel C
    PLoS One; 2023; 18(10):e0293302. PubMed ID: 37856531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation.
    Wong CKH; Lau KTK; Chung MSH; Au ICH; Cheung KW; Lau EHY; Daoud Y; Cowling BJ; Leung GM
    Nat Med; 2024 Jan; 30(1):112-116. PubMed ID: 37913816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.
    Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X
    JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
    Lewnard JA; McLaughlin JM; Malden D; Hong V; Puzniak L; Ackerson BK; Lewin BJ; Kim JS; Shaw SF; Takhar H; Jodar L; Tartof SY
    Lancet Infect Dis; 2023 Jul; 23(7):806-815. PubMed ID: 36933565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.